Chemotherapy: Optimizing irinotecan regimens for colorectal cancer

Nature Reviews Clinical Oncology

Volumn 6, Issue 10, 2009, Pages 560-561

  Yim, Kein Leong ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN; RALTITREXED;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HUMAN; LOADING DRUG DOSE; METASTASIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SHOCK;

ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE II AS TOPIC; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; DRUG THERAPY, COMBINATION; FLUOROURACIL; FOLLOW-UP STUDIES; GENE FREQUENCY; GLUCURONOSYLTRANSFERASE; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; QUALITY OF LIFE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349779591     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.140     Document Type: Article

References (10)

1. Cunningham, D. et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352, 1413-1418 (1998).
2. Douillard, J. Y. et al. irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355 1041-1047 (2000).
3. Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study Group. N. Engl. J. Med. 343, 905-914 (2000).
4. Seymour, M. T. et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370, 143-152 (2007).
5. Bidard, F. C. et al. Efficacy of FOLFIRI-3 (irinotecan D1, D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Ann. Oncol. 20, 1042-1047 (2009).
6. Tournigand, C. et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J. Clin. Oncol. 24, 394-400 (2006).
7. Sobrero, A. F. et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 2311-2319 (2008).
8. Mabro, M. et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br. J. Cancer 94, 1287-1292 (2006).
9. Hebbar, M., Ychou, M. & Ducreux, M. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J. Cancer Res. Clin. Oncol. 135, 749-752 (2009).
10. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working Group. Recommendations from the EGAPP working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11, 15-20 (2009).